P

Pentixapharm Holding
PTP

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
€36.73M
EV
€29.75M
Shares Outstanding
24.78M
Beta
-
Industry
-

Wall Street View

Analyst Rating
BUY
Analyst Target Price
Number of Analysts
1
P/E 2025E
-
P/Revenue 2025E
-

Historical 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Forecasted 3Y Growth Rate

Revenue
EPS
Operating Cash Flow
Free Cash Flow

Margins & Returns

Gross Margin 2025E
-
Net Profit Margin 2025E
-
ROE 2025E
-
ROCE 2024
-28.55%

Dividends

DPS 2025E
-
Payout Ratio 2025E
-
Div. Yield 2025E
-
DPS Last 3Y CAGR

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Pentixapharm Holding AG

gainify

P

Pentixapharm Holding AG

PTP

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the prog...

Sector

Industry

CEO

Pleimes, Dirk

Employees

64

IPO Date

Headquarters

Robert-Rössle-Straße 10, Berlin, Berlin, 13125 Germany

📊 Stock Price & Performance

Based on current PTP analyst forecasts and market assumptions, the consensus price target for Pentixapharm Holding (PTP) is €11.72 for 2027. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated:

💰 Financial Metrics & Reports

The current Pentixapharm Holding (PTP) market capitalization is approximately €36.73M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Pentixapharm Holding's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:21 AM Eastern Time

In the most recently reported quarter, Pentixapharm Holding (PTP) generated €79.00K in revenue. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 4:31 AM Eastern Time

In the most recently reported fiscal year, Pentixapharm Holding (PTP) generated net income of €-13.98M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 4:31 AM Eastern Time

According to its latest quarterly filing, Pentixapharm Holding (PTP) reported EBITDA of €-3.62M, representing a -38226.32% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 4:31 AM Eastern Time

📅 Earnings & Dividends

In the most recently reported quarter, Pentixapharm Holding (PTP) revenue was €79.00K. Earnings per share (EPS) for the quarter were €-0.17. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 4:31 AM Eastern Time

Pentixapharm Holding (PTP) does not currently pay a dividend. Over the last twelve months (LTM), the company paid €0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 4:31 AM Eastern Time

📈 Analyst Information

Analyst assessments of whether Pentixapharm Holding (PTP) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Consensus price target: €11.72Implied return: +565.15% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated:

Based on the latest available analyst coverage, Pentixapharm Holding (PTP) currently carries a Buy consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated:

Like other publicly traded stocks, Pentixapharm Holding (PTP) shares are bought and sold on stock exchanges such as XTRA and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Pentixapharm Holding (PTP) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add PTP to your watchlist.

Pentixapharm Holding trades under the ticker symbol PTP on the XTRA stock exchange. The ticker PTP is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Pentixapharm Holding (PTP) employs approximately 64 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: January 1, 2026 at 12:21 AM Eastern Time

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.